Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06BA Centrally acting sympathomimetics
N06BA09 Atomoxetine
D02574 Atomoxetine hydrochloride (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Attention Deficit Hyperactivity Disorder Agents, Non-amphetamines
Atomoxetine
D02574 Atomoxetine hydrochloride (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D02574 Atomoxetine hydrochloride (JAN/USP)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03085 Selective norepinephrine reuptake inhibitor (NRI)
DG00970 Atomoxetine
D02574 Atomoxetine hydrochloride
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00970 Atomoxetine
D02574 Atomoxetine hydrochloride
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D02574 Atomoxetine hydrochloride (JAN/USP) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02574
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02574
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02574
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02574
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D02574
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03085 Selective norepinephrine reuptake inhibitor (NRI)
DG00970 Atomoxetine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00970 Atomoxetine